secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001493152-24-017354
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma completes enrollment of 78 subjects in Phase 2a study of CC-42344 for influenza A
--------------------------------------------------------------------------------

- Enrolled 78 healthy subjects in randomized, double-blind, placebo-controlled Phase 2a human challenge study of oral PB2 inhibitor CC-42344.
- Study evaluating safety, tolerability, antiviral and clinical measurements of CC-42344 for pandemic and seasonal influenza A.
- Topline results expected later this year; study conducted in the United Kingdom.
- Company also plans to begin Phase 1 study in Australia with inhaled formulation of CC-42344.
- Received positive Pre-IND feedback from FDA in March 2024 guiding Phase 2b protocol.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224017354/0001493152-24-017354-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315224017354/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-017354

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer